Jouke T. Annema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jouke T. Annema has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Klaus F. Rabe
Division of Pulmonary Medicine, Leiden University Medical Center, Leiden, The Netherlands
7 shared publicationsMaud Veseliç
Longziekten, C3-P, Leids Universitair Medisch Centrum
7 shared publicationsM. Veseliç
Department of Pathology, Leiden University Medical Center, the Netherlands
4 shared publicationsK. F. Rabe
Department of Pulmonology, Leiden University Medical Center
3 shared publicationsK. Rabe
3 shared publicationsMichel I. Versteegh
3 shared publications
Latest Publications
- 1 September 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (9) , 1510-1515
Transesophageal Ultrasound-Guided Fine-Needle Aspiration for the Mediastinal Restaging of Non-small Cell Lung Cancer
- 1 September 2011
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 6 (9) , 1510-1515
Transesophageal Ultrasound-Guided Fine-Needle Aspiration for the Mediastinal Restaging of Non-small Cell Lung Cancer
- Top Cited PapersOpen Access
- 24 November 2010
- Published by American Medical Association (AMA) in JAMA
- Vol. 304 (20) , 2245-2252
Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer
Lung cancer is the most commonly diagnosed cancer worldwide (1.35 million/year) and also the most frequent cause of cancer death (1.18 million/year).1 Clinical staging of lung cancer is an integral part of patient care because it directs therapy and has prognostic value. Imaging with computed tomography (CT) is valuable for assessing the primary tumor (T-stage) while fluorodeoxyglucose positron emission tomography (PET) is valuable for detecting metastases. In cases where the primary tumor is resectable and in the absence of distant metastases, mediastinal nodal involvement (N-stage) directs treatment. Surgical resection of the tumor is the treatment of choice in the absence of mediastinal nodal metastases,2 whereas combined modality treatment is indicated for patients with mediastinal nodal metastases.3
- 24 November 2010
- Published by American Medical Association (AMA) in JAMA
- Vol. 304 (20) , 2245-2252
Top Cited PapersOpen AccessMediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer
Lung cancer is the most commonly diagnosed cancer worldwide (1.35 million/year) and also the most frequent cause of cancer death (1.18 million/year).1 Clinical staging of lung cancer is an integral part of patient care because it directs therapy and has prognostic value. Imaging with computed tomography (CT) is valuable for assessing the primary tumor (T-stage) while fluorodeoxyglucose positron emission tomography (PET) is valuable for detecting metastases. In cases where the primary tumor is resectable and in the absence of distant metastases, mediastinal nodal involvement (N-stage) directs treatment. Surgical resection of the tumor is the treatment of choice in the absence of mediastinal nodal metastases,2 whereas combined modality treatment is indicated for patients with mediastinal nodal metastases.3
- 1 January 2010
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 71 (1) , 64-70.e1
Implementation of endoscopic ultrasound for lung cancer staging
- 1 January 2010
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 71 (1) , 64-70.e1
Implementation of endoscopic ultrasound for lung cancer staging
- 22 December 2009
- Published by Elsevier in Annals of Oncology
- Vol. 21 (7) , 1468-1471
Transesophageal endoscopic ultrasound-guided fine-needle aspiration for the mediastinal staging of extrathoracic tumors: a new perspective
Background: Several extrathoracic tumors metastasize to the mediastinum. Mediastinoscopy is the standard method to obtain tissue proof of mediastinal spread, but drawbacks are its invasiveness, requirement for general anesthesia and costs. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is indicated in lung cancer staging guidelines as a minimally invasive alternative for surgical staging. The diagnostic values in patients with suspected mediastinal metastases and various (previous) extrathoracic malignancies were assessed. Patients and methods: Consecutive patients with suspected mediastinal metastases (on computed tomography or positron emission tomography) and an (previous) extrathoracic malignancy underwent EUS-FNA. Results: Seventy-five patients with current (n = 14) or previously diagnosed (n = 61) extrathoracic malignancies were evaluated. EUS-FNA detected mediastinal malignancies in 43 patients (57%) [metastases of extrathoracic tumors, n = 36 (48%); second malignancy (lung cancer), n = 7 (9%)]. Mediastinal metastases were found at subsequent surgical staging in seven patients or during follow-up (one patient). In seven patients, an alternative diagnosis was established. Sensitivity, specificity, accuracy and negative predictive value of EUS-FNA for mediastinal staging were 86%, 100%, 91% and 72%, respectively. Conclusion: EUS-FNA is a minimally invasive mediastinal staging method for patients with extrathoracic malignancies to confirm nodal metastatic spread and therefore may qualify as an alternative for surgical staging.
- 22 December 2009
- Published by Elsevier in Annals of Oncology
- Vol. 21 (7) , 1468-1471
Transesophageal endoscopic ultrasound-guided fine-needle aspiration for the mediastinal staging of extrathoracic tumors: a new perspective
Background: Several extrathoracic tumors metastasize to the mediastinum. Mediastinoscopy is the standard method to obtain tissue proof of mediastinal spread, but drawbacks are its invasiveness, requirement for general anesthesia and costs. Transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is indicated in lung cancer staging guidelines as a minimally invasive alternative for surgical staging. The diagnostic values in patients with suspected mediastinal metastases and various (previous) extrathoracic malignancies were assessed. Patients and methods: Consecutive patients with suspected mediastinal metastases (on computed tomography or positron emission tomography) and an (previous) extrathoracic malignancy underwent EUS-FNA. Results: Seventy-five patients with current (n = 14) or previously diagnosed (n = 61) extrathoracic malignancies were evaluated. EUS-FNA detected mediastinal malignancies in 43 patients (57%) [metastases of extrathoracic tumors, n = 36 (48%); second malignancy (lung cancer), n = 7 (9%)]. Mediastinal metastases were found at subsequent surgical staging in seven patients or during follow-up (one patient). In seven patients, an alternative diagnosis was established. Sensitivity, specificity, accuracy and negative predictive value of EUS-FNA for mediastinal staging were 86%, 100%, 91% and 72%, respectively. Conclusion: EUS-FNA is a minimally invasive mediastinal staging method for patients with extrathoracic malignancies to confirm nodal metastatic spread and therefore may qualify as an alternative for surgical staging.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7606
EUS-FNA as staging tool in resectable pleural mesothelioma
7606 Background: Patients with limited (cT1–3N0–1) malignant pleural mesothelioma (MPM) are potential candidates for trimodality therapy with induction chemotherapy, extrapleural pneumonectomy and hemithoracic irradiation. Since invasion of the mediastinal lymph nodes (MLN) is a negative prognostic factor, cervical mediastinoscopy has been recommended for staging. Transesophageal endoscopic ultrasound (EUS) and real-time guided fine needle aspiration (FNA) enables MLN staging in lung cancer patients with high accuracy. This study determined the feasibility and diagnostic yield of EUS-FNA in MPM, in comparison to the gold standard surgical-pathological staging. Methods: In this prospective two-center study, eligible patients had pathologically confirmed and potentially resectable MPM. Staging was performed by spiral-CT, PET, EUS-FNA and, irrespective of the EUS-FNA results, by cervical mediastinoscopy. Subsequently, patients had cisplatin and pemetrexed chemotherapy, which was in case of response or stable disease, followed by extrapleural pneumonectomy and MLN dissection. Results: Thirty-two consecutive patients (26 males; 25 right-sided) were registered from June 2004 until January 2007. Median age was 59 years (range 40–67). There were 2 sarcomatous, 26 epithelial and 4 biphasic subtypes. EUS was performed in all patients, in 7/32 without FNA since no lymph nodes > 5 mm were seen. EUS-FNA showed malignant cells amid a lymphocyte background in 4 (19%). Cervical mediastinoscopy was subsequently performed in 27 (84%) patients, which revealed no additional patients with MLN metastasis. In 11 patients, negative EUS-FNA was not confirmed by thoracotomy, mainly due to disease progression and clinical deterioration. Thoracotomy revealed a single level MLN metastasis at Naruke 4R in one patient, which was detected by neither EUS-FNA nor mediastinoscopy. Sensitivity of EUS- FNA for MLN metastases was 80% (95%-confidence limit 28–99%), specificity 95% (79–100%), NPV 94% (71–99%) and PPV 100% (39–100%). Conclusions: This is the first prospective study of EUS-FNA in MPM. EUS-FNA seems both a feasible and reliable tool for mediastinal staging in patients with potentially resectable MPM. Cervical mediastinoscopy in addition to EUS-FNA did not contribute to the detection of MLN metastases. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7606
EUS-FNA as staging tool in resectable pleural mesothelioma
7606 Background: Patients with limited (cT1–3N0–1) malignant pleural mesothelioma (MPM) are potential candidates for trimodality therapy with induction chemotherapy, extrapleural pneumonectomy and hemithoracic irradiation. Since invasion of the mediastinal lymph nodes (MLN) is a negative prognostic factor, cervical mediastinoscopy has been recommended for staging. Transesophageal endoscopic ultrasound (EUS) and real-time guided fine needle aspiration (FNA) enables MLN staging in lung cancer patients with high accuracy. This study determined the feasibility and diagnostic yield of EUS-FNA in MPM, in comparison to the gold standard surgical-pathological staging. Methods: In this prospective two-center study, eligible patients had pathologically confirmed and potentially resectable MPM. Staging was performed by spiral-CT, PET, EUS-FNA and, irrespective of the EUS-FNA results, by cervical mediastinoscopy. Subsequently, patients had cisplatin and pemetrexed chemotherapy, which was in case of response or stable disease, followed by extrapleural pneumonectomy and MLN dissection. Results: Thirty-two consecutive patients (26 males; 25 right-sided) were registered from June 2004 until January 2007. Median age was 59 years (range 40–67). There were 2 sarcomatous, 26 epithelial and 4 biphasic subtypes. EUS was performed in all patients, in 7/32 without FNA since no lymph nodes > 5 mm were seen. EUS-FNA showed malignant cells amid a lymphocyte background in 4 (19%). Cervical mediastinoscopy was subsequently performed in 27 (84%) patients, which revealed no additional patients with MLN metastasis. In 11 patients, negative EUS-FNA was not confirmed by thoracotomy, mainly due to disease progression and clinical deterioration. Thoracotomy revealed a single level MLN metastasis at Naruke 4R in one patient, which was detected by neither EUS-FNA nor mediastinoscopy. Sensitivity of EUS- FNA for MLN metastases was 80% (95%-confidence limit 28–99%), specificity 95% (79–100%), NPV 94% (71–99%) and PPV 100% (39–100%). Conclusions: This is the first prospective study of EUS-FNA in MPM. EUS-FNA seems both a feasible and reliable tool for mediastinal staging in patients with potentially resectable MPM. Cervical mediastinoscopy in addition to EUS-FNA did not contribute to the detection of MLN metastases. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7605
Implementation of transesophageal ultrasound (EUS-FNA) for lung cancer staging
7605 Background: Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) demonstrated to be an accurate and minimally invasive method for the diagnosis and staging of lung cancer, resulting in a reduced need for surgical staging in around half of patients. Although EUS-FNA is part of lung cancer staging algorithms in recent guidelines, no data exist whether the reported EUS findings—obtained by experts—are reproducible in community hospital settings. Methods: Prospective non-randomized multicenter diagnostic implementation trial. Nine physicians from 5 hospitals participated in a dedicated EUS implementation program including indication assessment and on-site training in 45 patients. Patients with (suspected) non- small cell lung cancer in whom surgical staging of the mediastinum was indicated were eligible. Consecutive patients underwent EUS-FNA in the 5 implementation centers as well as the single expert center. In case of the absence of tissue proven N2/N3 metastases at EUS-FNA, surgical staging or thoracotomy with mediastinal dissection was performed. Primary outcomes were: 1) sensitivity and accuracy regarding mediastinal staging and 2) prevented surgical interventions. Results of implementation centers were compared to that to the expert center. Results: 527 patients were included, 334 (63%) in the implementation and 193 (37%) in the expert center. Sensitivity and accuracy for mediastinal staging (implementation vs expert centers) were 83% and 89% vs 81 and 87% respectively. Surgical staging was spared due to endosonography in 47% (implementation) vs 46% (expert) of patients. Non representative FNA samples were identical (7%) in both groups. One major complication occurred in each group. No differences in the major outcomes were found in the implementation centers comparing results of the first with the second year after introduction of EUS-FNA. Conclusions: Chest physicians without prior (endo)sonography experience obtained the same sensitivity, accuracy and impact on patient management as experts, in performing EUS-FNA for the diagnosis and staging of lung cancer. The proposed implementation program might qualify as a model to facilitate large scale dissemination of EUS-FNA for lung cancer staging. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7605
Implementation of transesophageal ultrasound (EUS-FNA) for lung cancer staging
7605 Background: Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) demonstrated to be an accurate and minimally invasive method for the diagnosis and staging of lung cancer, resulting in a reduced need for surgical staging in around half of patients. Although EUS-FNA is part of lung cancer staging algorithms in recent guidelines, no data exist whether the reported EUS findings—obtained by experts—are reproducible in community hospital settings. Methods: Prospective non-randomized multicenter diagnostic implementation trial. Nine physicians from 5 hospitals participated in a dedicated EUS implementation program including indication assessment and on-site training in 45 patients. Patients with (suspected) non- small cell lung cancer in whom surgical staging of the mediastinum was indicated were eligible. Consecutive patients underwent EUS-FNA in the 5 implementation centers as well as the single expert center. In case of the absence of tissue proven N2/N3 metastases at EUS-FNA, surgical staging or thoracotomy with mediastinal dissection was performed. Primary outcomes were: 1) sensitivity and accuracy regarding mediastinal staging and 2) prevented surgical interventions. Results of implementation centers were compared to that to the expert center. Results: 527 patients were included, 334 (63%) in the implementation and 193 (37%) in the expert center. Sensitivity and accuracy for mediastinal staging (implementation vs expert centers) were 83% and 89% vs 81 and 87% respectively. Surgical staging was spared due to endosonography in 47% (implementation) vs 46% (expert) of patients. Non representative FNA samples were identical (7%) in both groups. One major complication occurred in each group. No differences in the major outcomes were found in the implementation centers comparing results of the first with the second year after introduction of EUS-FNA. Conclusions: Chest physicians without prior (endo)sonography experience obtained the same sensitivity, accuracy and impact on patient management as experts, in performing EUS-FNA for the diagnosis and staging of lung cancer. The proposed implementation program might qualify as a model to facilitate large scale dissemination of EUS-FNA for lung cancer staging. No significant financial relationships to disclose.
- 21 February 2008
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 2 (2) , 65-66
Novel lung cancer staging algorithms
- 21 February 2008
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 2 (2) , 65-66
Novel lung cancer staging algorithms
- 26 June 2006
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 38 (S 1) , 118-122
State of the art lecture: EUS and EBUS in pulmonary medicine
The development of linear echo-endoscopes has opened up fascinating new diagnostic possibilities for patients with various lung diseases. Transoesophageal ultrasound-guided fine needle aspiration (EUS-FNA) and transbronchial ultrasound-guided needle aspiration (EBUS-TBNA) are both minimally invasive diagnostic techniques that enable real-time controlled aspirations of mediastinal lymph nodes and centrally located lung tumours. By demonstrating mediastinal metastases, surgical procedures can frequently be avoided. In this short survey, we provide an overview concerning results obtained by EUS and EBUS in pulmonary medicine and discuss how these novel methods can be used in clinical practise.
- 26 June 2006
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 38 (S 1) , 118-122
State of the art lecture: EUS and EBUS in pulmonary medicine
The development of linear echo-endoscopes has opened up fascinating new diagnostic possibilities for patients with various lung diseases. Transoesophageal ultrasound-guided fine needle aspiration (EUS-FNA) and transbronchial ultrasound-guided needle aspiration (EBUS-TBNA) are both minimally invasive diagnostic techniques that enable real-time controlled aspirations of mediastinal lymph nodes and centrally located lung tumours. By demonstrating mediastinal metastases, surgical procedures can frequently be avoided. In this short survey, we provide an overview concerning results obtained by EUS and EBUS in pulmonary medicine and discuss how these novel methods can be used in clinical practise.